Any current/future new fundraising through debt or equity?

Tatva Chintan Pharma Chem Limited is in the process of raising funds amounting to Rs. 200 crore through a Qualified Institutions Placement (QIP), which involves issuing new shares, leading to capital infusion into the company. The QIP will likely reduce promoter stake below 75%, aligning with SEBI guidelines. The funds are intended for the next phase of expansion, including development on newly acquired land awaiting environmental clearance. The company has already utilized approximately 97% of net proceeds from an earlier fundraising totaling Rs. 2072.81 million. No specific mention o

Any current/future capex/capital investment/strategic investment?

The company is raising approximately Rs. 200 crore through a Qualified Institutional Placement (QIP) to fund the next phase of expansion. Proceeds will be used for the development of a new piece of land bought in 2021, which is on the verge of receiving environmental clearance (possibly by August or soon after). The company expects to reach about 80-85% utilization of the newly expanded Dahej facility in the next financial year and is planning further expansion. The Rs. 150 crore expanded Dahej plant's commercial production has commenced, with expectations for higher utilization from December

Future growth expectations in sales/revenue/volumes?

Steady improvement expected over coming quarters with favorable product mix driving growth. Revenue grew 29% YoY to ₹1,144 million in Q1 FY2024; EBITDA up 40% YoY, indicating strong profitability. New product commercialization, especially in pharma and agro intermediates, expected to start contributing from Q4 FY2024 and early 2025. Energy storage/electrolyte salts segment to see strong growth with four customers engaged; key turning point expected in calendar year 2025. Flame retardants segment to stabilize with production starting September 2023; revenue guidance of ₹25-40 crore for current

Future growth expectations in earnings/operating earnings/profits/EPS?

Gross margins expected to recover to around 55% by Q3 FY2024 as inventory clearance completes and product mix improves (Parth Mehta & Chintan Shah). Utilization of the newly expanded Dahej facility expected to reach 80-85% by FY2025, enhancing cost absorption and margins. EBITDA margins projected to improve with ramp-up in SDA demand, electrolyte salts, and flame retardant segments from Q4 FY2024. Stabilization and slight recovery in pricing for key products after earlier price corrections, supporting margin improvement. Depreciation expense increased due to recent capex, but no one-offs expec

Current/ Expected Orderbook/ Pending Orders?

Two agrochemical products are currently on the production floor at a plant scale for customer validation, with commercial supplies expected to begin by late December 2023 or early January 2024. Additionally, two pharmaceutical products are under validation and expected to commercialize in early 2025. Out of these four products, two were mentioned in the previous quarter's order book; the other two are new additions. The company is expanding its pipeline with products in the pilot stage aimed at commercialization. For the electrolyte segment, the company is working towards pilot-scale delivery

Tatva Chintan Pharma Chem LtdQ1 FY24Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,743P/E: 80.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Steady improvement expected over coming quarters with favorable product mix driving growth.
Revenue grew 29% YoY to ₹1,144 million in Q1 FY2024; EBITDA up 40% YoY, indicating strong profitability.
New product commercialization, especially in pharma and agro intermediates, expected to start contributing from Q4 FY2024 and early 2025.
Energy storage/electrolyte salts segment to see strong growth with four customers engaged; key turning point expected in calendar year 2025.
Flame retardants segment to stabilize with production starting September 2023; revenue guidance of ₹25-40 crore for current fiscal maintained.
Capacity utilization expected to ramp up to ~80-85% in expanded Dahej facility by next financial year supporting volume growth.
QIP funding to support next phase of expansion, target increasing capacity and product pipeline.
Anticipated gross margin normalization and better pricing to sustain profitability.
SDA segment demand expected to ramp up strongly by end 2023, aiding revenue growth.

Margin guidance

Category 2

Gross margins expected to recover to around 55% by Q3 FY2024 as inventory clearance completes and product mix improves (Parth Mehta & Chintan Shah).
Utilization of the newly expanded Dahej facility expected to reach 80-85% by FY2025, enhancing cost absorption and margins.
EBITDA margins projected to improve with ramp-up in SDA demand, electrolyte salts, and flame retardant segments from Q4 FY2024.
Stabilization and slight recovery in pricing for key products after earlier price corrections, supporting margin improvement.
Depreciation expense increased due to recent capex, but no one-offs expected; steady quarterly depreciation going forward.
Revenue growth expected from increased commercial production, new product approvals, and entry into new markets.
QIP fund raise (~Rs.200 crore) intended to support next-phase expansions, indicating confidence in sustained growth.
Overall outlook: steady earnings growth and margin expansion from late FY2024 and into FY2025 as operations scale and pricing stabilizes.

See what Tatva Chintan Pharma Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Tatva Chintan Pharma Chem Limited is in the process of raising funds amounting to Rs. 200 crore through a Qualified Institutions Placement (QIP), which involves issuing new shares, leading to capital infusion into the company.
The QIP will likely reduce promoter stake below 75%, aligning with SEBI guidelines.
The funds are intended for the next phase of expansion, including development on newly acquired land awaiting environmental clearance.
The company has already utilized approximately 97% of net proceeds from an earlier fundraising totaling Rs. 2072.81 million.
No specific mention of new debt fundraising was reported in the most recent call; however, interest costs remain high due to increased benchmark rates, with the last scheduled repayment of existing term loans in Q1 of next year.

Order book

Yes

Two agrochemical products are currently on the production floor at a plant scale for customer validation, with commercial supplies expected to begin by late December 2023 or early January 2024.
Additionally, two pharmaceutical products are under validation and expected to commercialize in early 2025.
Out of these four products, two were mentioned in the previous quarter's order book; the other two are new additions.
The company is expanding its pipeline with products in the pilot stage aimed at commercialization.
For the electrolyte segment, the company is working towards pilot-scale delivery with expectations to start commercial activity by December 2023.
The order book is supported by steady demand and ongoing product qualification efforts, indicating a healthy outlook for future orders.

See what Tatva Chintan Pharma Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is raising approximately Rs. 200 crore through a Qualified Institutional Placement (QIP) to fund the next phase of expansion.
Proceeds will be used for the development of a new piece of land bought in 2021, which is on the verge of receiving environmental clearance (possibly by August or soon after).
The company expects to reach about 80-85% utilization of the newly expanded Dahej facility in the next financial year and is planning further expansion.
The Rs. 150 crore expanded Dahej plant's commercial production has commenced, with expectations for higher utilization from December 2023.
The capital expenditure will involve capacity enhancement particularly at Dahej and accelerating the launch of new products.
QIP issuance will dilute promoter stake below 75%, complying with SEBI guidelines.
Long-term focus on developing ultra-high purity products and entering new segments such as semiconductor materials and electrolyte salts for energy storage systems.

Track Tatva Chintan Pharma Chem Ltd — get its next earnings analysis in your feed

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisTatva Chintan Pharma Chem Ltd

Rev 2Mar 2

See where Tatva Chintan Pharma Chem Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Compare Tatva Chintan Pharma Chem Ltd against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Tatva Chintan Pharma Chem Ltd Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season